Zhang Z - Search Results

1

Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation.

Zhang Z, Zhang R. Zhang Z, et al. Among authors: zhang r. EMBO J. 2008 Mar 19;27(6):852-64. doi: 10.1038/emboj.2008.25. Epub 2008 Feb 28. EMBO J. 2008. PMID: 18309296 Free PMC article.

2

Quercetin induces tumor-selective apoptosis through downregulation of Mcl-1 and activation of Bax.

Cheng S, Gao N, Zhang Z, Chen G, Budhraja A, Ke Z, Son YO, Wang X, Luo J, Shi X. Cheng S, et al. Among authors: zhang z. Clin Cancer Res. 2010 Dec 1;16(23):5679-91. doi: 10.1158/1078-0432.CCR-10-1565. Clin Cancer Res. 2010. PMID: 21138867 Free PMC article.

3

Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels.

Li M, Zhang Z, Hill DL, Chen X, Wang H, Zhang R. Li M, et al. Among authors: zhang r, zhang z. Cancer Res. 2005 Sep 15;65(18):8200-8. doi: 10.1158/0008-5472.CAN-05-1302. Cancer Res. 2005. PMID: 16166295

4

Cadmium induces intracellular Ca2+- and H2O2-dependent apoptosis through JNK- and p53-mediated pathways in skin epidermal cell line.

Son YO, Lee JC, Hitron JA, Pan J, Zhang Z, Shi X. Son YO, et al. Among authors: zhang z. Toxicol Sci. 2010 Jan;113(1):127-37. doi: 10.1093/toxsci/kfp259. Epub 2009 Nov 3. Toxicol Sci. 2010. PMID: 19887573 Free PMC article.

5

Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.

Li M, Zhang Z, Hill DL, Wang H, Zhang R. Li M, et al. Among authors: zhang r, zhang z. Cancer Res. 2007 Mar 1;67(5):1988-96. doi: 10.1158/0008-5472.CAN-06-3066. Cancer Res. 2007. PMID: 17332326

6

Novel MDM2 p53-independent functions identified through RNA silencing technologies.

Zhang Z, Wang H, Li M, Rayburn E, Agrawal S, Zhang R. Zhang Z, et al. Among authors: zhang r. Ann N Y Acad Sci. 2005 Nov;1058:205-14. doi: 10.1196/annals.1359.030. Ann N Y Acad Sci. 2005. PMID: 16394138 Review.

7

Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Zhang Z, et al. Among authors: zhang r. Am J Pharmacogenomics. 2005;5(6):397-407. doi: 10.2165/00129785-200505060-00006. Am J Pharmacogenomics. 2005. PMID: 16336004 Review.

8

Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.

Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R. Zhang Z, et al. Among authors: zhang r. Oncogene. 2005 Nov 3;24(48):7238-47. doi: 10.1038/sj.onc.1208814. Oncogene. 2005. PMID: 16170383

9

Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases.

Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Zhang Z, et al. Among authors: zhang r. Am J Pharmacogenomics. 2005;5(3):173-90. doi: 10.2165/00129785-200505030-00004. Am J Pharmacogenomics. 2005. PMID: 15952871 Review.

10

p53-independent activities of MDM2 and their relevance to cancer therapy.

Zhang Z, Zhang R. Zhang Z, et al. Among authors: zhang r. Curr Cancer Drug Targets. 2005 Feb;5(1):9-20. doi: 10.2174/1568009053332618. Curr Cancer Drug Targets. 2005. PMID: 15720185 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results